Palatin Technologies, Inc.
AMEX•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Carl Spana Ph.D.
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Cedar Brook Corporate Center Cranbury NJ United States of America 08512
- IPO Date
- Oct 15, 1997
- CIK
- 0000911216
- Website
- palatin.com
- Similar Companies
- Business
- Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Company News
Palatin Appeals NYSE American Notice of Delisting
NYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)
Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Palatin Provides Update on Anticipated 2025 Corporate Milestones
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity